Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases

详细信息    查看全文

• 作者：Clara Abraham<sup>1sup><sup> ; sup><sup>clara.abraham@yale.edusup> ; Parambir S. Dulai<sup>2sup> ; Sé ; verine Vermeire<sup>3sup> ; William J. Sandborn<sup>2sup>
• 关键词：Crohn&rsquo ; s Disease ; Ulcerative Colitis ; Therapy ; Intestine
• 刊名：Gastroenterology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：152
• 期：2
• 页码：374-388.e4
• 全文大小：1870 K
• 卷排序：152

文摘

Insights into the pathogenesis of inflammatory bowel diseases (IBDs) have provided important information for the development of therapeutics. Levels of interleukin 23 (IL23) and T-helper (Th) 17 cell pathway molecules are increased in inflamed intestinal tissues of patients with IBD. Loss-of-function variants of the IL23-receptor gene (IL23R) protect against IBD, and, in animals, blocking IL23 reduces the severity of colitis. These findings indicated that the IL23 and Th17 cell pathways might be promising targets for the treatment of IBD. Clinical trials have investigated the effects of agents designed to target distinct levels of the IL23 and Th17 cell pathways, and the results are providing insights into IBD pathogenesis and additional strategies for modulating these pathways. Strategies to reduce levels of proinflammatory cytokines more broadly and increase anti-inflammatory mechanisms also are emerging for the treatment of IBD. The results from trials targeting these immune system pathways have provided important lessons for future trials. Findings indicate the importance of improving approaches to integrate patient features and biomarkers of response with selection of therapeutics.